The snakebite epidemic in India is a dire crisis, claiming the lives of tens of thousands each year.
In a heart-wrenching account shared by Devendra, a former farmer, he recalls the moment he was bitten by a snake while gathering mulberry leaves. "I went to the hospital four days after the bite, but by then, the pain was unbearable. The delay ultimately cost me my leg," he reveals in a poignant short film released by the Global Snakebite Taskforce (GST), an organization dedicated to decreasing fatalities and injuries caused by snakebites.
Devendra's survival places him among a fortunate few. Official statistics from the Indian government indicate that approximately 50,000 individuals succumb to snakebites annually—this figure represents about half of the global death toll. However, some estimates suggest that the actual numbers could be even more staggering; data from 2000 to 2019 indicates that India might have experienced up to 1.2 million deaths, averaging around 58,000 fatalities per year, as reported by a study in 2020.
A recent report from GST has revealed alarming challenges faced by healthcare providers in India regarding the administration of antivenom—the critical serum that counteracts venom toxins. Researchers conducted surveys involving 904 medical professionals across India, Brazil, Indonesia, and Nigeria, which are nations heavily impacted by snakebites. They discovered similar obstacles: inadequate infrastructure, limited access to antivenom, and insufficient training.
Almost half of the surveyed healthcare workers noted that delays in treatment frequently led to severe complications for their patients, resulting in amputations, surgeries, or chronic mobility issues. Additionally, the report highlights that snakebites disproportionately affect impoverished rural communities in low- and middle-income countries.
In India, the central and eastern regions report a high incidence of snakebite fatalities and injuries, according to Dr. Yogesh Jain, a GST member and practitioner in Chhattisgarh. He emphasizes that the most vulnerable populations are those working in agriculture, particularly within underprivileged tribal communities.
In response to this pressing issue, India introduced the National Action Plan for Prevention and Control of Snakebite Envenoming (NAPSE) in 2024, aiming to halve snakebite-related deaths by the year 2030. This initiative focuses on enhancing surveillance, improving access to antivenom, bolstering medical capabilities, and conducting public awareness campaigns.
Experts largely view this initiative as a positive development; however, they note that its implementation has been inconsistent. "In India, snakebites are often perceived as a problem for the underprivileged, which may explain the lack of outrage or action regarding these preventable deaths," Jain remarks. "In snakebite cases, every second counts."
He clarifies that venom enters the bloodstream rapidly, potentially causing damage to nerves, cells, or the circulatory system depending on the snake species involved. Delaying antivenom treatment can lead to dire consequences such as respiratory failure, paralysis, irreversible tissue damage, or organ failure.
Rural India often grapples with delays in hospitalization due to poor road conditions, distant medical facilities, and insufficient ambulance services. A tragic incident last September illustrates this issue: a pregnant woman in Gujarat lost her life while being carried for 5 kilometers in a cloth sling to reach a hospital due to inaccessible roads.
Some states are attempting to improve antivenom access by stocking it in primary and community health centers, yet proper administration remains a significant obstacle. Many healthcare workers lack formal training and express concerns about administering antivenom, as patients sometimes experience adverse reactions.
"Antivenom needs to be mixed with saline and administered intravenously over an hour, but many facilities aren’t equipped to handle potential side effects," Jain explains. Furthermore, many rural residents still rely on traditional healers or local remedies, seeking hospital care only after their condition deteriorates—a delay that can prove fatal.
Gerry Martin, co-founder of The Liana Trust, an organization based in Karnataka that aims to mitigate human-snake conflict, identifies another critical challenge: the accessibility of high-quality antivenom. Presently, India produces antivenom effective only against the so-called "big four" snakes—the spectacled cobra, common krait, Russell's viper, and saw-scaled viper—believed to account for the majority of snakebites. Martin elaborates that this antivenom is derived from injecting venom from these snakes into horses, whose antibodies are then utilized as a treatment for humans.
However, there are numerous other venomous snake species in India for which targeted antivenom is not available. This includes the green pit viper found in Himachal Pradesh, the Malabar pit viper, and the hump-nosed pit viper in southern states, among many others in northeastern regions. A study conducted by the All India Institute of Medical Sciences (AIIMS) in Rajasthan last year exposed these gaps, revealing that when antivenom intended for saw-scaled viper bites was administered to patients with unidentified snake species, two-thirds did not respond adequately to treatment. The researchers concluded that there is an urgent need for region-specific antivenom, particularly in western India.
For the past five years, The Liana Trust has been working to analyze venoms from additional species beyond the big four in hopes of developing effective antidotes. Nonetheless, progress has been sluggish, as the process is both labor-intensive and time-consuming. Martin has urged states to follow Karnataka’s 2024 directive that classified snakebites as a "notifiable disease," necessitating healthcare professionals to report occurrences to authorities to combat under-reporting.
Jain concurs, stating, "The fight against snakebite deaths begins where political will ends. Governments must ensure that people in lower socioeconomic strata do not receive inferior healthcare. They deserve better."
This narrative raises a pivotal question: why does the plight of snakebite victims remain overlooked in a nation of immense progress? What actions can we take to advocate for equitable healthcare solutions? Share your thoughts below!
